Trials / Completed
CompletedNCT01185002
Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Medtronic - MITG · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to test the effect of a bowel preparation and boosts regimen on PillCam® procedure, colon cleanliness and capsule excretion time.
Detailed description
Interim analysis will be done after 20 subjects are enrolled in order to assess the 1st arm. Following the analysis of the first phase results, and per need, 30 more subjects may be enrolled under a different regimen (2nd arm). Second Interim analysis will be done in order to assess the 2nd phase results. Following the analysis of the 2nd phase results, and per need, up to 30 additional subjects may be enrolled under a third regimen (3rd arm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PillCam® COLON 2 procedure using MgC boosts | Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts. |
| OTHER | PillCam® COLON 2 procedure using Suprep boosts | Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts |
| OTHER | PillCam® COLON 2 procedure using reduced dose of Suprep boosts | Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-08-19
- Last updated
- 2019-07-31
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01185002. Inclusion in this directory is not an endorsement.